Algorae Pharmaceuticals Ltd
Research Algorae Pharmaceuticals Ltd (1AI) on Bullrun: market cap AUD 18.25M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1AI
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 18.25M
- Financial periodFY2025
- RevenueAUD 3.87M
- Revenue growth43.8%
- Net income-AUD 6.17M
- Free cash flow-AUD 3.84M
- Gross margin3.2%
Valuation Snapshot
latest market cap is AUD 18.25M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 3.87M | -AUD 6.17M | -AUD 3.84M | 3.2% | 0 | AUD 3.99M | AUD 7.07M | -AUD 4.89M |
| FY2024 | AUD 2.69M | -AUD 2.10M | -AUD 1.52M | 27.5% | 0 | AUD 3.11M | AUD 6.49M | AUD 3.01M |
| FY2023 | n/a | -AUD 2.11M | -AUD 1.99M | n/a | 0 | AUD 6.13M | n/a | AUD 3.76M |
| FY2022 | AUD 0 | -AUD 1.96M | -AUD 2.05M | n/a | 0 | AUD 7.24M | n/a | AUD 4.03M |
| FY2021 | n/a | -AUD 1.46M | -AUD 1.46M | n/a | n/a | AUD 1.57M | n/a | AUD 1.38M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-30 | AUD 18.25M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Algorae Pharmaceuticals Ltd
Algorae Pharmaceuticals Limited, an AI-enabled pharmaceutical development company, engages in the research and development of living cells technologies primarily in Australia and New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Algorae Pharmaceuticals Ltd's market cap?
Algorae Pharmaceuticals Ltd's market capitalization is AUD 18.25M.
What does Algorae Pharmaceuticals Ltd do?
Algorae Pharmaceuticals Limited, an AI-enabled pharmaceutical development company, engages in the research and development of living cells technologies primarily in Australia and New Zealand.